Navigation Links
The Modern Algorithm For Management Of Massive And Submassive Pulmonary Embolism
Date:11/21/2013

NEW YORK, Nov. 21, 2013 /PRNewswire-iReach/ -- Acute pulmonary embolism (PE) is a potentially life-threatening condition, reporting an overall mortality rate of 15% in the first three months after diagnosis. The literature describes a three-tier risk stratification scale (massive, submassive and minor) based on the hemodynamic status and presence of signs/symptoms.  Tod C. Engelhardt, MD, Louisiana Heart, Lung and Vascular Institute, East Jefferson General Hospital (Metairie, LA) reported at the 40th Annual VEITHsymposium in New York stating, "Massive PE patients present with critical conditions, such as severe right ventricular (RV) dysfunction, systemic arterial hypotension or cardiogenic shock, and require immediate intervention. Submassive PE patients, while systemically normotensive, exhibit RV dysfunction and are typically managed conservatively. These patients represent a serious unmet need for advanced therapy to restore the hemodynamic impairment, given that RV dysfunction if unresolved promptly predicts poor outcome, including death."

(Photo:  http://photos.prnewswire.com/prnh/20131121/MN18404)

Engelhardt reports that intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rtPA) allows reversal of hemodynamic compromise and gas exchange derangement, and is considered a life-saving therapy for massive PE patients. For submassive PE patients, the recently completed PEITHO trial demonstrated a reduction of a combined endpoint of 7-day cardiopulmonary collapse and mortality with treatment by IV Tenecteplase compared to placebo. However, widespread adoption of IV thrombolysis is hampered by increased risk of major bleeding, including intracranial hemorrhage reported at 3% historically and at 2% specifically in PEITHO.  Engelhardt said, "Ultrasound-accelerated thrombolysis (USAT), enabled by the EkoSonic® Endovascular System is an advanced catheter-directed modality that facilitates localized delivery of rtPA into the pulmonary thrombus. The ultrasonic energy increases thrombus permeability and facilitates deep penetration of the drug into the thrombus, which accelerates clot dissolution using only a fraction the standard IV rtPA dose."

In his presentation Engelhardt cited his institutional approach for acute PE, employs USAT as the primary therapy for both massive and submassive patients. Upon identification of signs/symptoms consistent with PE and confirmation of PE by computer tomographic angiography (CTA) of the chest, the patient is referred to Cardiovascular and Thoracic Surgery. Based on presence of RV strain defined as the right-ventricle-to-left-ventricle diameter (RV/LV) ratio at end-diastole exceeding 0.9, the patient undergoes USAT using a low-dose rtPA infusion protocol.  The early experience with USAT examined varied doses and infusion durations.  He went on to report that the current protocol has been standardized to a total dose of 24 mg rtPA infused at 1.0 mg/hour/catheter (12 hours in bilateral; 24 hours in unilateral PE) with no bolus.  

Engelhardt emphasized, "We retrospectively evaluated PE patients treated with USAT with follow-up chest CTA at 48±6 hours post infusion.  57 patients (age 58±15 yrs) have been included during the study period from 2009-2013, with 15 new patients enrolled since last reported in 2012. There were 7 massive and 50 submassive PE cases.  52 patients (91%) presented with bilateral PE. Overall, a rtPA dose of 29.5±14.8 mg was infused over 17.2±6.6 hours. Following USAT, the RV/LV ratio was reduced from 1.5±0.4 at baseline to 1.0±0.2 at follow-up CTA (p<0.001). 30-day follow-up CTA available in 6 patients demonstrated further decrease of the RV/LV ratio (to a range of 0.6-0.9). Overall, median length of stay was 1 day in the ICU and 7 days in the hospital. All patients were discharged alive. There were no systemic bleeding complications, but 4 access site bleeding complications requiring transfusion and 1 suspected recurrent massive PE event; all reported in our early experience involving higher rtPA doses at the range of 45 mg, but no bleeds reported in the current protocol with 24 mg. In summary, our analysis demonstrated rapid resolution of RV dysfunction among both massive and submassive PE patients from USAT, with evidence of continued improvement with time." "These results support that the catheter-based modality allows hemodynamic recovery consistent with that observed in IV thrombolysis, while minimizing the serious bleeding risks associated with IV therapy," concluded Engelhardt.

About VEITHsymposium: Now in its fourth decade, VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease.

The 5-day event features over 750 rapid-fire presentations from world-renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. To register to attend the VEITHsymposium, please visit www.VEITHpress.org or contact Pauline T. Mayer at 631.979.3780 or email.

Media Contact: Pauline Mayer, PTM Healthcare Marketing, Inc., 631-979-3780, ptm@ptmhcm.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE VEITHsymposium
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Demand for Faster Healing Spurs Sale of Advanced Wound Care and Modern Wound Closure Devices in Asia-Pacific
2. Neues vorfüllbares Spritzensystem bietet hochmoderne Glastechnologie für die Verabreichung injizierbarer biopharmazeutischer Medikamente
3. Modern Medical Introduces Opioid Abuse Solution to the Workers Compensation Industry
4. Valencia College verwendet hochmoderne Simbionix-Simulatoren für Ausbildungsprogramm im Bereich kardiovaskulärer Technologie
5. The Thousand-Year Business Model for a Modern Biopharmaceutical Company
6. The Medicus Firm Named 2012 "Best Places to Work in Healthcare" by Modern Healthcare
7. Intrepid Investment Bankers LLC Advises A-Med Health Care in the Sale of its Specialty Pharmacy Assets to Modern HC Pharmacy, Inc., a portfolio company of Altamont Capital Partners
8. Blood Pressure Management Changed on Global Level with OSTARs 3SI Interpretive Blood Pressure Algorithm
9. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
10. CDC Article Shows IMOs Interface Terminology Beats Algorithms for Identifying Coronary Heart Disease with Nearly Perfect Accuracy
11. MedQIA unique CAD algorithm for Quantitation of lung involvement in diffuse lung disease used as treatment efficacy end point in study to be reported at the ERS Annual Conference in Vienna, Austria: September 1-5, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... 2017  For nearly two decades, New Life Agency has been committed ... industry. Today, New Life Agency announces a powerful three-way partnership designed to ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... ... Excellence (CoE) with the latest Artificial Intelligence (AI) thinking, announced today the launch ... and easy access to essential information that offers a more comprehensive understanding of ...
(Date:9/20/2017)... ... September 20, 2017 , ... Renal ... for people who have kidney disease. The theme “Describe a positive decision that ... Entrants needed to meet only one qualification— to have been diagnosed with ...
(Date:9/20/2017)... Houston, TX (PRWEB) , ... September 20, 2017 ... ... the date of the much-anticipated fall event , Look Awesome This Autumn ... demonstrations, personalized consultations, special pricing and refreshments. , Mirror Mirror Beauty Boutique ...
(Date:9/20/2017)... ... September 20, 2017 , ... As part of ... recently unveiled a redesigned website. The new site – still located at ... architects, contractors and other industry users that Garland serves. , After an ambitious ...
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short time since going on ... positive feedback from customers trying the product for the first time, and others who ... developed by neurosurgeon Shawn Moore, MD, for everyone from athletes at risk from multiple ...
Breaking Medicine News(10 mins):